CBT-509 (Cytotoxic T-lymphocyte Antigen-4)

  • A novel IgG1 humanized monoclonal antibody against the cytotoxic T-lymphocyte antigen-4 receptor on tumor cells.
  • CBT Pharmaceuticals retains with worldwide rights.